: Akero's results showed the potential for cirrhosis reversal, which temporarily overshadowed Madrigal's market position.
The "dip" was primarily triggered by releasing positive Phase 2b data for its drug efruxifermin in patients with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). MadrigalВ Dip
The consensus among firms like TipRanks is that Madrigal’s treatment could become a "blockbuster," supported by its first-mover advantage in the space. : Akero's results showed the potential for cirrhosis
: Following this news, Madrigal shares traded down roughly 5% . Investment Sentiment MadrigalВ Dip